AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

Rivaroxaban 2.5 Mg ;

9 registrations across 1 African market— 9 active

Markets with Rivaroxaban 2.5 Mg ;

Recent registrations

Brand / ProductMarketHolderStatusExpires
Kemiroxaban 2.5 mg
Film Coated Tablets
🇪🇬EgyptChemipharm Pharmaceutical Industriesactive
Rivaxarelt 2.5 mg
Film Coated Tablets
🇪🇬Egyptpenta pharma egyptactive
Xanoxiban 2.5 mg
Film Coated Tablets
🇪🇬EgyptHikma pharmaactive
Vaxato 2.5 mg
Film Coated Tablets
🇪🇬EgyptThe Tenth of Ramadan for Pharmaceutical Industries & Diagnostic Reagents "RAMEDA"active
Repatoxaban 2.5 mg
Film Coated Tablets
🇪🇬EgyptEVAPHARMA for Pharmaceutical Industries ( EVAPHARMA)active
Vaxato 2.5 mg
Film Coated Tablets
🇪🇬EgyptThe Tenth of Ramadan for Pharmaceutical Industries & Diagnostic Reagents "RAMEDA"active
Orgoroxaban 2.5 mg
Film Coated Tablets
🇪🇬Egyptorgano for pharmaceutical and chemical industries (organo pharma)active
Repatoxaban 2.5 mg
Film Coated Tablets
🇪🇬EgyptEVAPHARMA for Pharmaceutical Industries ( EVAPHARMA)active
Andorivaban 2.5 mg
Film Coated Tablets
🇪🇬Egyptal andalous for pharmaceutical industriesactive

Rivaroxaban 2.5 Mg ; in Africa — Regulatory Overview

Rivaroxaban 2.5 Mg ; is registered across 1 African markets with 9 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Egypt. AfricaRegulatory refreshes this data daily from official government sources.

Of the 9 registrations, 9 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.